In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price target of $230.00. The company’s shares closed yesterday at $108.83.
According to TipRanks, Prasad is a 2-star analyst with an average return of 0.0% and a 39.57% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Zoetis, and Alvotech.
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $189.92.
Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $972.14 million and a net profit of $146.82 million. In comparison, last year the company earned a revenue of $940.65 million and had a GAAP net loss of $19.65 million
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals (JAZZ) Company Description:
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Read More on JAZZ:
- Jazz completes rolling submission of BLA for zanidatamab antibody
- Jazz Pharmaceuticals price target raised to $188 from $171 at Piper Sandler
- Jazz Pharmaceuticals price target raised to $230 from $225 at Stifel
- Zymeworks price target raised to $14 from $12 at Wells Fargo
- Avadel Pharmaceuticals price target raised to $22 from $20 at Needham
